Buy Dr Reddys Labs; target of Rs 2161: PLilladher

Prabhudas Lilladher is bullish on Dr Reddys Labs and has recommended buy rating on the stock with a target of Rs 2161 in its February 15, 2013 research report.
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead master your money SME Special
moneycontrol.com

Home » News » Recommendations

Feb 19, 2013, 02.21 PM | Source: Moneycontrol.com

Buy Dr Reddys Labs; target of Rs 2161: PLilladher

Prabhudas Lilladher is bullish on Dr Reddys Labs and has recommended buy rating on the stock with a target of Rs 2161 in its February 15, 2013 research report.

Like this story, share it with millions of investors on M3

Buy Dr Reddys Labs; target of Rs 2161: PLilladher

Prabhudas Lilladher is bullish on Dr Reddys Labs and has recommended buy rating on the stock with a target of Rs 2161 in its February 15, 2013 research report.

Post Your Comments

Share Cancel

(more)

, Prabhudas Lilladher |

Prabhudas Lilladher is bullish on Dr Reddys Labs and has recommended buy rating on the stock with a target of Rs 2161 in its February 15, 2013 research report.
 
“DRRD’s Q3FY13 result was below our estimates due to muted performance in the US and domestic formulation segment. During the quarter, EBITDA margins remained subdued due to adverse product mix and increase in R&D expenditure. However, the company is expected to continue to report strong performance, going forward, led by all-round growth.”
 
“DRRD’s core revenue for the quarter reported growth of 24 percent YoY to Rs28.7bn, primarily led by formulation exports to emerging markets and PSAI business led by new product launches by customers. However, the domestic formulation business and US reported muted growth of 11.6 percent and 30 percent, respectively. DRRD reported 12 percent YoY increase in core EBITDA during the quarter to Rs5.87bn, while core EBITDA margins contracted by 230bps YoY to 20.5 percent impacted by adverse product mix and increased R&D expense. Despite this, Adj. PAT reported strong growth of 33 percent to Rs3.8bn, led by lower tax rate compared to Q3FY12.”
 
“We expect strong 28 percent earnings CAGR over FY12-14 on the back of 16 percent revenue CAGR and benefit of operating leverage. We remain positive on the overall business prospects of the company over medium term, led by strong US generic business and growth traction in branded business. The stock is currently valued at 20.4x FY13E EPS and 17.3x FY14E EPS. The stock trades at 10-15 percent discount to its historic and peer valuation. We reiterate .BUY. with target price of Rs 2161,” says Prabhudas Lilladher research report.     
Institutional holding more than 40% in Indian cos

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

To read the full report click here

Ads by Google

Buy, Hold, Sell ? Hear it first on M3
Buy Dr Reddys Labs; target of Rs 2161: PLilladher

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login